{"meshTagsMajor":["Codon","Mutation"],"meshTags":["Adult","Aged","Antineoplastic Combined Chemotherapy Protocols","Benzimidazoles","Carcinoma, Non-Small-Cell Lung","Codon","Female","Humans","Lung Neoplasms","Male","Middle Aged","Mutation","Neoplasm Staging","Proto-Oncogene Proteins","Proto-Oncogene Proteins p21(ras)","Retrospective Studies","Taxoids","ras Proteins"],"meshMinor":["Adult","Aged","Antineoplastic Combined Chemotherapy Protocols","Benzimidazoles","Carcinoma, Non-Small-Cell Lung","Female","Humans","Lung Neoplasms","Male","Middle Aged","Neoplasm Staging","Proto-Oncogene Proteins","Proto-Oncogene Proteins p21(ras)","Retrospective Studies","Taxoids","ras Proteins"],"genes":["KRAS codon subtypes","KRAS mutant","KRAS mutant","KRAS codon mutations","KRAS G12C","KRAS mutations"],"publicationTypes":["Clinical Trial, Phase II","Journal Article","Randomized Controlled Trial","Research Support, Non-U.S. Gov\u0027t"],"abstract":"Selumetinib (AZD6244, ARRY-142886)+docetaxel increases median overall survival (OS) and significantly improves progression-free survival (PFS) and objective response rate (ORR) compared with docetaxel alone in patients with KRAS mutant, stage IIIB/IV non-small-cell lung cancer (NSCLC; NCT00890825).\nRetrospective analysis of OS, PFS, ORR and change in tumour size at week 6 for different sub-populations of KRAS codon mutations.\nIn patients receiving selumetinib+docetaxel and harbouring KRAS G12C or G12V mutations there were trends towards greater improvement in OS, PFS and ORR compared with other KRAS mutations.\nDifferent KRAS mutations in NSCLC may influence selumetinib/docetaxel sensitivity.","title":"Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer.","pubmedId":"26125448"}